Talibegron

Drug Profile

Talibegron

Alternative Names: ICI D 2079; SCH 417849; ZD 2079

Latest Information Update: 07 Feb 2003

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Small molecules
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 07 Feb 2003 Discontinued - Phase-II for Obesity in United Kingdom (unspecified route)
  • 01 Mar 2001 A study has been added to the Obesity pharmacodynamics section
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top